Euphorbia lathyris A, its preparation method and application

By isolating and purifying Euphorbia lunata A, the problem of screening effective neuroprotective active ingredients in the existing technology has been solved, and high-purity Euphorbia lunata A and its neuroprotective effect have been achieved. It is suitable for the preparation of a variety of neuroprotective drug dosage forms.

CN123106598APending Publication Date: 2026-11-17QIQIHAR MEDICAL UNIVERSITY
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202611285279.1
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2026-08-24
Publication Date
2026-11-17

AI Technical Summary

Technical Problem

In the existing technology, Euphorbia lunulae has been used for a long time, but there is a lack of systematic chemical separation methods to improve the quality standards of its neuroprotective active ingredients, making it difficult to effectively screen out compounds with significant in vitro neuroprotective effects.

Method used

Euphorbia lunata was isolated and purified by ethanol extraction, macroporous resin separation, silica gel column chromatography and high performance liquid chromatography to obtain a new compound, Euphorbia lunata terpene A, which was then used to prepare neuroprotective drugs, including injections, lyophilized powder injections and oral preparations.

Benefits of technology

Euphorbia pekinensis A significantly reversed the H2O2-induced decrease in intracellular 5-hydroxytryptamine levels in HT22 cells, demonstrating good in vitro neuroprotective activity and increasing intracellular 5-hydroxytryptamine levels, thus possessing neuroprotective effects.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN123106598A_ABST
    Figure CN123106598A_ABST
Patent Text Reader

Abstract

This invention relates to a novel substance with in vitro neuroprotective activity, its preparation method, and its application. The novel substance, euphorbia lunulata A, has the molecular formula C2. 20 H 28 O4. Preparation: 1. Cold extraction with ethanol; 2. Dispersing the ethanol-recovered extract in water and loading it onto D101 macroporous resin; 3. Repeated separation of the ethanol-eluting fraction from the macroporous resin by silica gel column chromatography, followed by high-performance liquid chromatography, yielding the product, named Euphorbia lunata A. Euphorbia lunata A is used as an active ingredient in the preparation of in vitro neuroprotective drugs. Euphorbia lunata A described in this invention exerts its neuroprotective effect by reversing the damage effect of H2O2-induced decrease in intracellular 5-hydroxytryptamine levels in HT22 cells. This compound exhibits good in vitro neuroprotective activity. This invention belongs to the field of extraction of effective components from natural drugs.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] This invention relates to a novel substance with in vitro neuroprotective properties, its preparation method, and its applications. Background Technology

[0002] Euphorbia lunulata, listed in the 2025 edition of the Chinese Pharmacopoeia, is a traditional Chinese medicinal herb. It is bitter and pungent in taste, neutral in nature, and toxic. It has the effects of draining water and promoting urination, breaking up accumulations and killing parasites. It is mainly used to treat edema and abdominal distension, phlegm and food stagnation, abdominal pain, tuberculosis, scabies, etc.

[0003] Modern pharmacological studies have shown that the main active components of Euphorbia lunulata are diterpenoids, which have anti-tumor, anti-inflammatory, antibacterial, antifungal, antiviral and anti-epileptic effects, making it a valuable source of phytoneurothermic drugs.

[0004] Currently, there are many preparations of Euphorbia lunulae on the market. However, as a medicinal plant that has been used for a long time, it is of great significance to carry out systematic chemical separation of Euphorbia lunulae in order to improve its quality standards and discover more indicative components with neuroprotective activity.

[0005] Oxidative stress is a pathological state in which the body's oxidative and antioxidant systems are disrupted after exposure to various harmful stimuli, leading to the excessive generation of free radicals such as reactive oxygen species (ROS) and reactive nitrogen species, exceeding the clearance capacity of the cellular antioxidant defense system and ultimately causing cell and tissue damage. Neuroprotection is an intervention strategy that uses multiple approaches, including drug intervention, lifestyle modifications, and physical therapy, to prevent, delay, or alleviate nerve cell damage and inhibit the decline of neurological function. Its core function is to maintain the integrity of the nervous system's structure and normal physiological function, protecting various vulnerable neurons, including hippocampal neurons involved in learning and memory regulation, and substantia nigra neurons, which are prone to damage in Parkinson's disease and involved in motor function regulation. HT22 cells are derived from mouse hippocampal neuronal cell lines, and the hippocampus plays a crucial role in learning and memory. Constructing an HT22 cell oxidative damage model using H2O2, screening compounds with significant cytoprotective effects, and conducting systems pharmacological and toxicological studies will contribute to the development of novel neuroprotective drugs and provide more drug candidates for the clinical treatment of nervous system-related diseases. Summary of the Invention

[0006] The purpose of this invention is to provide a novel compound with in vitro neuroprotective activity, its preparation method, and its application.

[0007] The molecular formula of Euphorbia lathyris A is C 20 H 28 O4, the molecular structural formula is:

[0008] The molecular weight is 332.1988.

[0009] The preparation method of euphorbia lathyrin A is carried out according to the following steps:

[0010] 1. Place Euphorbia lunata in the extraction tank of a Soxhlet dynamic extraction and concentration unit, and extract with ethanol to obtain ethanol extract;

[0011] 2. After concentrating the extract obtained in step 1, disperse it with water onto D101 macroporous resin, and elute it sequentially with a mixed solvent of methanol and water at volume concentrations of 0%, 20%, 40%, and 60%, respectively.

[0012] 3. The eluent obtained in step 2, consisting of a 60% (v / v) methanol and water mixture, was separated by silica gel column chromatography. The eluent was then eluted sequentially with mixed solvents of petroleum ether and ethyl acetate at volume ratios of 100:0, 80:1, 50:1, and 30:1. The eluent at a volume ratio of 30:1 was further separated by silica gel column chromatography. The eluent was then eluted sequentially with mixed solvents of dichloromethane and methanol at volume ratios of 100:0, 80:1, and 50:1. The eluent at a volume ratio of 50:1 (v / v) dichloromethane and methanol was collected. A high-performance liquid chromatography (HPLC) chromatogram was prepared using a 55:45 (v / v) acetonitrile and water mixture as the mobile phase at a flow rate of 3 mL / min. The absorption peak appearing at 25.5 min was collected, yielding Euphorbia lathyris A.

[0013] Furthermore, the pressure of the Soxhlet dynamic extraction and concentration unit described in step one is set to normal temperature and normal pressure extraction.

[0014] Furthermore, the high-performance liquid chromatography (HPLC) chromatograms described in step three were acquired using a Waters 2535 semi-preparative HPLC system, with C0.05... 18 The reversed-phase silica gel column was used as the packing material, and the Waters 2414 differential detector was used as the detector.

[0015] The application of the euphorbia lunata A, wherein the euphorbia lunata A is used as an active ingredient in the preparation of neuroprotective drugs.

[0016] Furthermore, the dosage forms of the neuroprotective drugs include injections, lyophilized powder injections, and oral preparations.

[0017] Furthermore, the oral formulations include tablets, granules, soft capsules, hard capsules, oral liquids, and sustained-release formulations.

[0018] Furthermore, the euphorbia terpenoid A, as a neuroprotective agent, includes reversing damage caused by H2O2-induced decrease in intracellular serotonin levels in HT22 cells.

[0019] The chemical name of the euphorbia lanuginosa A of this invention is 8,14-dihydroxy-17,18,19,20-tetramethyl-decahydrophenanthro-furan-16-one, and its molecular formula is C16. 20 H 28 O4.

[0020] The compounds described in this invention can be formulated into pharmaceutically acceptable solid or liquid formulations by adding pharmaceutically acceptable excipients.

[0021] There are no restrictions on the excipients used in this invention, as long as they are pharmaceutically acceptable.

[0022] Beneficial effects: Compared with the prior art, the present invention has the following advantages:

[0023] This invention provides a novel compound derived from Euphorbia lunata and a method for extracting, separating, and purifying the novel compound. The method employs ethanol extraction, macroporous resin, silica gel column chromatography, and preparative high-performance liquid chromatography for separation and purification, successfully obtaining the novel compound. The operation method is simple and rapid, and the compound obtained by this method has high purity. Furthermore, studies have shown that the above compound has neuroprotective activity.

[0024] This novel compound exerts neuroprotective effects by reversing the damage caused by H2O2-induced decrease in 5-hydroxytryptamine levels in HT22 cells. Results showed that 25 μM and 50 μM euphorbia lindane A increased the downregulated 5-HT levels in H2O2-damaged HT22 cells from 2.5 ng / mL to 2.8 ng / mL and 3.1 ng / mL, respectively, indicating that the compound possesses good in vitro neuroprotective activity. Euphorbia lindane A of this invention can be formulated into injections, lyophilized powders for injection, infusions, or oral preparations (including tablets, granules, soft capsules, hard capsules, oral solutions, and sustained-release formulations) as neuroprotective drugs. Attached Figure Description

[0025] Figure 1 This is the MS image of Euphorbia lathyris A.

[0026] Figure 2 This is the UV spectrum of Euphorbia lathyris A;

[0027] Figure 3 It is Euphorbia lathyris A. 1 H-NMR spectrum;

[0028] Figure 4 It is Euphorbia lathyris A. 13 C-NMR spectrum;

[0029] Figure 5 This is the DEPT plot of Euphorbia lathyris A;

[0030] Figure 6 This is the HSQC spectrum of Euphorbia lathyris A;

[0031] Figure 7 This is the HMBC spectrum of Euphorbia lathyris A;

[0032] Figure 8 It is Euphorbia lathyris A. 1 H- 1 H-COSY spectrum;

[0033] Figure 9 This is the NOESY spectrum of Euphorbia lathyris A;

[0034] Figure 10 This is the IR spectrum of Euphorbia lathyris A;

[0035] Figure 11 This is the standard curve for the determination of 5-hydroxytryptamine content in Experiment 2;

[0036] Figure 12 This is a diagram illustrating the effect of Euphorbia lathyris A on improving the reduction of 5-hydroxytryptamine content in H2O2-induced HT22 cells in Experiment 2. Detailed Implementation

[0037] The technical solution of the present invention is not limited to the specific embodiments listed below, but also includes any combination of the specific embodiments.

[0038] Specific Implementation Method 1: The molecular formula of Euphorbia lathyris A in this implementation method is C 20 H 28 O4, the molecular structural formula is:

[0039] The molecular weight is 332.1988.

[0040] Specific Implementation Method Two: The preparation method of Euphorbia lathyris A described in Specific Implementation Method One is carried out according to the following steps:

[0041] 1. Place Euphorbia lunata in the extraction tank of a Soxhlet dynamic extraction and concentration unit, and extract with ethanol to obtain ethanol extract;

[0042] 2. After concentrating the extract obtained in step 1, disperse it with water onto D101 macroporous resin, and elute it sequentially with a mixed solvent of methanol and water at volume concentrations of 0%, 20%, 40%, and 60%, respectively.

[0043] 3. The eluent obtained in step 2, consisting of a 60% (v / v) methanol and water mixture, was separated by silica gel column chromatography. The eluent was then eluted sequentially with mixed solvents of petroleum ether and ethyl acetate at volume ratios of 100:0, 80:1, 50:1, and 30:1. The eluent at a volume ratio of 30:1 was further separated by silica gel column chromatography. The eluent was then eluted sequentially with mixed solvents of dichloromethane and methanol at volume ratios of 100:0, 80:1, and 50:1. The eluent at a volume ratio of 50:1 (v / v) dichloromethane and methanol was collected. A high-performance liquid chromatography (HPLC) chromatogram was prepared using a 55:45 (v / v) acetonitrile and water mixture as the mobile phase at a flow rate of 3 mL / min. The absorption peak appearing at 25.5 min was collected, yielding Euphorbia lathyris A.

[0044] Specific Implementation Method Three: This implementation method differs from Specific Implementation Method Two in that the pressure of the Soxhlet dynamic extraction and concentration unit described in step one is set to ambient temperature and atmospheric pressure extraction. Everything else is the same as in Specific Implementation Method One or Two.

[0045] Specific Implementation Method Four: This implementation method differs from one of Specific Implementation Methods Two or Three in that the high-performance liquid chromatography (HPLC) chromatograms described in step three are acquired using a Waters 2535 semi-preparative HPLC system, with C0.05 as the standard value. 18 The reversed-phase silica gel column is used as the packing material, and a Waters 2414 differential detector is used as the detector. Everything else is the same as in one of specific embodiments two or three.

[0046] Specific Implementation Method 5: This implementation method, along with Specific Implementation Methods 1 to 4, uses Euphorbia lathyris A as an active ingredient to prepare neuroprotective drugs.

[0047] Specific Implementation Method Six: This implementation method differs from Specific Implementation Method Five in that the dosage form of the neuroprotective drug includes injections, lyophilized powder injections, and oral preparations. Everything else is the same as in Specific Implementation Method Five.

[0048] Specific Implementation Method Seven: This implementation method differs from Specific Implementation Method Six in that the oral preparations include tablets, granules, soft capsules, hard capsules, oral liquids, and sustained-release preparations. Everything else is the same as in Specific Implementation Method Six.

[0049] Specific Implementation Method Eight: This implementation method differs from Specific Implementation Method Five in that the neuroprotection includes reversing the damage caused by the decrease in intracellular 5-hydroxytryptamine levels induced by H2O2. Everything else is the same as in Specific Implementation Method Five.

[0050] The following experiments were used to verify the effectiveness of the invention:

[0051] Experiment 1:

[0052] Euphorbia lunulata A, the molecular formula of Euphorbia lunulata A is C20 H 28 O4, the molecular structural formula is:

[0053] The molecular weight is 332.1988.

[0054] The preparation method of the euphorbia lunulae A is carried out according to the following steps:

[0055] 1. Place Euphorbia lunata in the extraction tank of a Soxhlet dynamic extraction and concentration unit, and extract with ethanol to obtain ethanol extract;

[0056] 2. After concentrating the extract obtained in step 1, disperse it with water onto D101 macroporous resin, and elute it sequentially with a mixed solvent of methanol and water at volume concentrations of 0%, 20%, 40%, and 60%, respectively.

[0057] 3. The eluent obtained in step 2, consisting of a 60% (v / v) methanol and water mixture, was separated by silica gel column chromatography. The eluent was then eluted sequentially with mixed solvents of petroleum ether and ethyl acetate at volume ratios of 100:0, 80:1, 50:1, and 30:1. The eluent at a volume ratio of 30:1 was further separated by silica gel column chromatography. The eluent was then eluted sequentially with mixed solvents of dichloromethane and methanol at volume ratios of 100:0, 80:1, and 50:1. The eluent at a volume ratio of 50:1 (v / v) dichloromethane and methanol was collected. A high-performance liquid chromatography (HPLC) chromatogram was prepared using a 55:45 (v / v) acetonitrile and water mixture as the mobile phase at a flow rate of 3 mL / min. The absorption peak appearing at 25.5 min was collected, yielding Euphorbia lathyris A.

[0058] The pressure of the Soxhlet dynamic extraction and concentration unit described in step one is set to normal temperature and normal pressure extraction.

[0059] The high-performance liquid chromatography (HPLC) chromatograms described in step three were acquired using a Waters 2535 semi-preparative HPLC system, with C0.05 as the chromatogram. 18 The reversed-phase silica gel column was used as the packing material, and the Waters 2414 differential detector was used as the detector.

[0060] The chemical name of the euphorbia lanuginosa A of this invention is 8,14-dihydroxy-17,18,19,20-tetramethyl-decahydrophenanthro-furan-16-one, and its molecular formula is C16. 20 H 28 O4.

[0061] This experiment used 30 kg of dried Euphorbia lunata, and finally obtained 2.22 mg of Euphorbia lunata terpene A. Table 1 shows the NMR data of the new compound Euphorbia lunata terpene A (using CD3OD).1 H-NMR and 13 C-NMR test).

[0062] Table 1: NMR data of the novel compound Euphorbia lathyris A of this invention

[0063]

[0064] The final molecular structure of Euphorbia lathyris A was determined to be:

[0065] .

[0066] Based on its structure, the euphorbia lunata A was named 8,14-dihydroxy-17,18,19,20-tetramethyl-decahydrophenanthro-furan-16-one.

[0067] Experiment 2:

[0068] The euphorbia lunulae A prepared in Experiment 1 was used to conduct experiments on its regulation of 5-hydroxytryptamine content in HT22 cells damaged by H2O2. The steps are as follows:

[0069] 1. Drug preparation

[0070] Euphorbia lathyris A was dissolved in DMSO to prepare a stock solution of 500 μmol / L. The solution was then diluted with PBS to test concentrations of 25 μmol / L and 50 μmol / L.

[0071] 2. Cell Culture

[0072] HT22 cells were cultured in DMEM high-glucose medium containing 10% fetal bovine serum and 1% double antibiotics in a 5% CO2 incubator at 37°C until they reached the logarithmic growth phase.

[0073] 3. ELISA method for detecting 5-hydroxytryptamine content

[0074] Supernatant from H2O2-damaged HT22 cells treated with 25 μmol / L and 50 μmol / L Euphorbia lysine A was used as the test sample. After equilibrating the kit foil pouch at room temperature for 10 min, the required ELISA strips were removed. The remaining strips were sealed and stored at 4℃. 50 μL of the test supernatant or sample was added to each well, and 50 μL of universal diluent was added to the blank wells. All samples and standards were replicated. The test supernatant was pre-diluted 1-fold with universal diluent to reduce matrix effects. Then, 50 μL of biotin antibody working solution was added to each well. The plate was sealed and incubated at 37℃ for 60 min. After incubation, the liquid in the wells was discarded. 300 μL of 1× washing buffer was added to each well, and the plate was allowed to stand for 1 min before being shaken dry and patted dry on absorbent paper. The plate was washed 3 times, or a plate washer could be used. After washing, 100 μL of enzyme conjugate working solution was added to each well. The plate was sealed and incubated at 37℃ for 30 minutes. After washing for 5 minutes, discard the solution again and repeat the washing procedure as described above. Then, add 90 μL of TMB substrate to each well, seal the plate, and incubate at 37°C for 15 minutes in the dark. Finally, remove the microplate and add 50 μL of stop solution to each well. Plot a standard curve with the concentration of 5-hydroxytryptamine on the x-axis and the OD value at 450 nm on the y-axis: y = 0.551x + 0.1686, R0 2 = 0.9922.

[0075] The results showed that the 5-hydroxytryptamine content in the control group HT22 was 3.8 ng / mL. 25 μM and 50 μM Euphorbia lysine A could increase the downregulated 5-hydroxytryptamine level in H2O2-damaged HT22 cells from 2.5 ng / mL to 2.8 ng / mL and 3.1 ng / mL, respectively, indicating that Euphorbia lysine A has good in vitro neuroprotective activity.

Claims

1. Euphorbia lathyris A, characterized in that... The molecular formula of the euphorbia lunulae A is C 20 H 28 O4, the molecular structural formula is: The molecular weight is 332.1988.

2. The method for preparing Euphorbia lathyris A according to claim 1, characterized in that, The preparation method of the euphorbia lunulae A is carried out according to the following steps:

1. Place Euphorbia lunata in the extraction tank of a Soxhlet dynamic extraction and concentration unit, and extract with ethanol to obtain ethanol extract; 2. After concentrating the extract obtained in step 1, disperse it with water onto D101 macroporous resin, and elute it sequentially with a mixed solvent of methanol and water at volume concentrations of 0%, 20%, 40%, and 60%, respectively.

3. The eluent obtained in step 2, consisting of a 60% (v / v) methanol and water mixture, was separated by silica gel column chromatography. The eluent was then eluted sequentially with mixed solvents of petroleum ether and ethyl acetate at volume ratios of 100:0, 80:1, 50:1, and 30:

1. The eluent at a volume ratio of 30:1 was further separated by silica gel column chromatography. The eluent was then eluted sequentially with mixed solvents of dichloromethane and methanol at volume ratios of 100:0, 80:1, and 50:

1. The eluent at a volume ratio of 50:1 (v / v) dichloromethane and methanol was collected. A high-performance liquid chromatography (HPLC) chromatogram was prepared using a 55:45 (v / v) acetonitrile and water mixture as the mobile phase at a flow rate of 3 mL / min. The absorption peak appearing at 25.5 min was collected, yielding Euphorbia lathyris A.

3. The method for preparing Euphorbia lathyris A according to claim 2, characterized in that, The pressure of the Soxhlet dynamic extraction and concentration unit described in step one is set to normal temperature and normal pressure extraction.

4. The method for preparing Euphorbia lathyris A according to claim 2, characterized in that, The high-performance liquid chromatography (HPLC) chromatograms described in step three were acquired using a Waters 2535 semi-preparative HPLC system, with C0.05 as the chromatogram. 18 The reversed-phase silica gel column was used as the packing material, and the Waters 2414 differential detector was used as the detector.

5. The application of the euphorbia terpenoid A according to claim 1, characterized in that, Euphorbia pekinensis A is used as an active ingredient in the preparation of neuroprotective drugs.

6. The application of Euphorbia lathyris A according to claim 5, characterized in that, The dosage forms of the neuroprotective drugs include injections, lyophilized powder injections, and oral preparations.

7. The application of Euphorbia lathyris A according to claim 6, characterized in that, The oral preparations include tablets, granules, soft capsules, hard capsules, oral liquids, and sustained-release preparations.

8. The application of Euphorbia lathyris A according to claim 5, characterized in that, The neuroprotection includes reversing the damage caused by H2O2-induced decrease in intracellular serotonin levels in HT22 cells.